Palvella Therapeutics has named Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services to support the upcoming U.S. launch of QTORIN™ rapamycin for rare skin diseases and vascular malformations. McDonough brings over 25 years of experience in rare disease commercial strategy, notably leading the successful launch of VYJUVEK® at Krystal Biotech. Her expertise will help Palvella build strong payer engagement, patient support, and specialty distribution as it advances its pipeline of therapies. This appointment strengthens Palvella's readiness for market entry and patient-centered care in rare disease treatment.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
